DECISIF: Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility

Sponsor
Assistance Publique - Hôpitaux de Paris (Other)
Overall Status
Completed
CT.gov ID
NCT03591848
Collaborator
(none)
186
1
2
18.2
10.2

Study Details

Study Description

Brief Summary

Comparative study of two information modalities during the care course, aiming to propose the preservation of fertility to young women with breast cancer (but not yet under treatment): standard oral information during the PF consultation vs. an online decision support tool, consulted prior to the PF consultation, during which the standard oral information is provided.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Online support decision tool
  • Behavioral: standard oral information
N/A

Detailed Description

In recent decades, the incidence of breast cancer has increased significantly among young women. Between 1980 and 2012, there was an increase of 59% and 53% in the 30-39 age group and the 40-49 age group, respectively. However, both diagnostic and therapeutic advances made it possible to significantly reduce mortality, at the cost of potentially deleterious chemotherapeutic treatments for reproductive function. These treatments may therefore be the cause of a chronic pathology "infertility" that may negatively impact the quality of life of young breast cancer survivors.

Since 2004, in France, the preservation of fertility (PF) is part of the different laws of bioethics. The latest cancer plans have highlighted the importance of quality of life in patients cured of cancer. For young women, this often involves the possibility of accessing maternity, using their own gametes. Thus, access to an onco fertility consultation should be systematically proposed, ideally before the initiation of any cancer treatment.

While the importance of oncofertility consultations is now recognized, they raise a certain number of ethical questions, particularly as to the nature of the information to be transmitted, whether it is generalizable or not, and how it is delivered and supported.

Very little data on the value of decision support tools in PF for women with breast cancer are available, while the concept of "shared medical decision" is becoming increasingly important in the doctor-patient relationship.

The only available studies have shown that these tools can reduce the level of decisional conflict and regret over fertility-related treatment options, and improve knowledge about fertility and satisfaction among young women.

This study aims to compare two modalities of delivery of information to breast cancer patients (not yet under treatment): standard oral information during the prevention of fertility (PF) consultation vs. an online decision support tool, consulted prior to the PF consultation, during which the standard oral information is provided.

Study Design

Study Type:
Interventional
Actual Enrollment :
186 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Participant)
Primary Purpose:
Supportive Care
Official Title:
Evaluation of an Online Decision Support Tool for Young Women With Breast Cancer During the Proposal for Preservation of Fertility
Actual Study Start Date :
Sep 9, 2018
Actual Primary Completion Date :
Mar 17, 2020
Actual Study Completion Date :
Mar 17, 2020

Arms and Interventions

Arm Intervention/Treatment
Experimental: DECISIF

Exposed to an online support decision tool, in addition of the standard oral information

Behavioral: Online support decision tool
Online support decision tool, in addition of the standard oral information

Behavioral: standard oral information
standard oral information

Active Comparator: IRIS

Exposed to a standard oral information

Behavioral: standard oral information
standard oral information

Outcome Measures

Primary Outcome Measures

  1. Multidimensional Measure of Informed Choice (MMIC) [1 day (During the PF consultation)]

    Measure of patient autonomy for making decision, according to the Multidimensional Measure of Informed Choice (MMIC). A series of closed questions (based on the Osgoog's scale) on their feelings about this fertility preservation approach, describing attitudes in regards to "good / bad", "important / unimportant", "unhelpful" good thing / bad thing, "" pleasant / unpleasant "and" useful / useless ". Responses go from "very positive" (1) to "very negative" (7).

Secondary Outcome Measures

  1. Decisional Conflict Scale Measure on [1 day (at the end of the PF consultation)]

    patient's decision-making discomfort, specific support needs for decision-making, the quality of decision making, the impact of supportive interventions on health decision-making.

  2. Anxiety [1 day ( at the end of the PF consultation)]

    : the 6 items of State and Trait Anxiety Inventory [55] [56], a reliable and sensitive measure of anxiety will be used to assess emotional disturbance. It consists of 6 items, indicating the lowest level of anxiety (1 = not at all) and 4 the highest (4 = very much), with a reverse rating items. The items are summated multiplied by 20 and divided by 6. Patients with scores> 50 are considered to have a high level of anxiety.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 40 Years
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • 18-40 years women

  • with breast cancer

  • cancer treatment not started, no antecedent of chemotherapy

  • speaking French

  • affiliated in Social Insurance

Exclusion Criteria:
  • recurrence of breast cancer

  • metastatic breast cancer

  • pregnancy in progress

  • Adults protected (wardship, guardianship, protection of justice)

Contacts and Locations

Locations

Site City State Country Postal Code
1 Reproduction medicine and fertility preservation ANTOINE BECLERE Hospital Clamart France 92140

Sponsors and Collaborators

  • Assistance Publique - Hôpitaux de Paris

Investigators

  • Principal Investigator: Michaël GRYNBERG, PhD, Assistance Publique - Hôpitaux de Paris

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Assistance Publique - Hôpitaux de Paris
ClinicalTrials.gov Identifier:
NCT03591848
Other Study ID Numbers:
  • K171005J
  • 2017-A03008-45
First Posted:
Jul 19, 2018
Last Update Posted:
Jan 8, 2021
Last Verified:
Dec 1, 2020
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Assistance Publique - Hôpitaux de Paris
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jan 8, 2021